American Oriental Bioengineering Inc (AOB) financial statements (2022 and earlier)

Company profile

Business Address NO, 4018 JINTIAN ROAD, ANLIAN PLAZA
FUTIAN, DISTRICT SHENZHEN, 518026
State of Incorp. CO
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2012
12/31/2011
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7,097
Cash and cash equivalents7,097
Receivables45,544
Inventory, net of allowances, customer advances and progress billings20,571
Inventory20,571
Prepaid expense227
Advances on inventory purchases10,065
Other current assets719
Other undisclosed current assets11,225
Total current assets:95,448
Noncurrent Assets
Property, plant and equipment171,381
Long-term investments and receivables3,337
Long-term investments3,337
Intangible assets, net (including goodwill)145,315
Intangible assets, net (excluding goodwill)145,315
Deferred costs267
Other undisclosed noncurrent assets30,560
Total noncurrent assets:350,860
TOTAL ASSETS:446,309
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities28,107
Accounts payable11,005
Accrued liabilities16,339
Taxes payable763
Debt6,873
Other undisclosed current liabilities71,231
Total current liabilities:106,212
Noncurrent Liabilities
Long-term debt and lease obligation555
Long-term debt, excluding current maturities555
Liabilities, other than long-term debt11,956
Deferred tax liabilities, net11,956
Total noncurrent liabilities:12,511
Total liabilities:118,722
Stockholders' equity
Stockholders' equity attributable to parent, including:327,587
Preferred stock1
Common stock73
Treasury stock, value(800)
Additional paid in capital177,974
Accumulated other comprehensive income71,790
Retained earnings78,098
Other undisclosed stockholders' equity attributable to parent451
Total stockholders' equity:327,587
TOTAL LIABILITIES AND EQUITY:446,309

Income statement (P&L) ($ in thousands)

12/31/2012
12/31/2011
Revenues145,100
Cost of revenue(100,742)
Gross profit:44,358
Operating expenses(130,689)
Operating loss:(86,331)
Nonoperating income
(Other Nonoperating income)
379
Interest and debt expense36,138
Loss from continuing operations before equity method investments, income taxes:(49,814)
Loss from equity method investments(2,813)
Other undisclosed loss from continuing operations before income taxes(4,874)
Loss from continuing operations before income taxes:(57,501)
Income tax expense(2,224)
Net loss:(59,725)
Net income attributable to noncontrolling interest12
Net loss available to common stockholders, diluted:(59,713)

Comprehensive Income ($ in thousands)

12/31/2012
12/31/2011
Net loss:(59,725)
Comprehensive loss:(59,725)
Comprehensive loss, net of tax, attributable to noncontrolling interest(12)
Other undisclosed comprehensive income, net of tax, attributable to parent4,092
Comprehensive loss, net of tax, attributable to parent:(55,646)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: